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Abstract
Background/aims To validate the use of the Test Your Memory (TYM) test in dementias other than Alzheimer’s disease, 
and to compare the TYM test to two other short cognitive tests.
Methods One hundred and fifty-seven patients with dementia other than typical Alzheimer’s disease were recruited from a 
specialist memory clinic. Patients completed the TYM test, the revised Addenbrooke’s Cognitive Examination (ACE-R) and 
Mini-Mental State Examination (MMSE), plus neurological examination, clinical diagnostics and multi-disciplinary team 
review. Their TYM scores were compared to age-matched controls and an Alzheimer’s disease cohort.
Results Patients scored an average of 34.4/50 on the TYM test compared to 46.0/50 in age-matched controls. Using the 
threshold of 42/50, the TYM test detected 80% of non-Alzheimer dementias. The area under the ROC curve was 0.89 with a 
PPV of 0.80 and a NPV of 0.84. The TYM test performed better than the ACE-R (using the threshold of 83) which detected 
69% of cases and the MMSE (using a threshold of 24) which detected only 27%.
Conclusions The TYM test is a useful test in the detection of non-Alzheimer dementia. The TYM test performs much better 
than the MMSE at detecting non-Alzheimer dementias.
Keywords Dementia · Alzheimer’s · Cognitive · TYM · Non-Alzheimer dementia · Sensitivity and specificity
Introduction
Dementia is a major health problem with the prevalence 
increasing as the population ages [1]. Alzheimer’s dis-
ease (AD) is the commonest form of dementia but many 
patients have non-Alzheimer dementias. Together, the non-
Alzheimer’s diseases represent up to 50% of dementia cases 
[1], and are substantial causes of morbidity and mortality 
globally. Examples include dementia with Lewy bodies 
(DLB), behavioural and language variants of frontotempo-
ral dementia (FTD), vascular dementia (VaD), progressive 
supranuclear palsy (PSP) and corticobasal syndrome (CBS). 
In addition, AD pathology can present atypically as posterior 
cortical atrophy (PCA) or logopaenic aphasia. The diagno-
sis of non-Alzheimer dementia is challenging. Patients with 
early dementia will normally present to non-specialists who 
have limited knowledge of less common dementias and the 
myriad ways in which they present.
The diagnosis of dementia requires a clinical assessment 
and examination which in most healthcare settings includes 
the completion of a short cognitive test (SCT) [2, 3]. It is 
important that any SCT used is sensitive to different forms 
of dementia not just AD. There has been little research into 
the use of SCTs in the diagnosis of non-Alzheimer demen-
tias. The Mini-Mental State Examination (MMSE) [4] is 
widely used and has been extensively investigated as a diag-
nostic test for dementia [5] but may be insensitive to some 
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non-Alzheimer dementias [6]. More recently devised tests 
such as the Addenbrooke’s Cognitive Examinations (ACE) 
[6, 7] and the Montreal Cognitive Assessment (MoCA) [8] 
are sensitive to some non-Alzheimer forms of dementia. 
However, both take significant time to administer and so 
are less used outside specialized memory clinics.
In 2009, a new SCT was published called “Test Your 
Memory” (TYM) [9] which was designed to test a wide 
range of cognitive functions using the minimum of medical 
time. It is self-administered by patients, under supervision, 
in contrast to the administration of revised Addenbrooke’s 
Cognitive Examination (ACE-R) and MoCA which need 
trained staff. The TYM test has been validated in the detec-
tion of AD in many different languages and cultures [10]. 
In the UK, it has been recommended by the National Insti-
tute for Health and Care Excellence as a validated cognitive 
assessment in non-specialist settings [3].
This study examines the properties of the TYM test in the 
diagnosis of non-Alzheimer dementia and compares it to the 
MMSE and the ACE-R.
Methods
Setting
Patients with non-Alzheimer’s dementia were enrolled from 
a UK memory clinic between May 2007 and October 2015. 
We aimed to recruit 20 patients with each non-Alzheimer 
dementia. A cross-sectional design was used to compare the 
TYM pattern of scoring and overall score with the clinical 
diagnosis. Patients were recruited prospectively, and tested 
during the clinical care visit. Recruitment was on a conveni-
ence basis, as NHS staff had time. Nurses administered the 
TYM test after the other SCTs in patients with suspected 
non-Alzheimer dementias. If the diagnosis was confirmed 
at the multi-disciplinary meeting, the patient was recruited. 
Data collection was complete and there were no drop outs.
Ethical approval for the study was obtained from the 
Cambridgeshire 2 Ethics committee.
All patients were seen by a consultant neurologist or psy-
chiatrist with a special interest in dementia. Patients had 
a full clinical assessment including history, neurological 
examination, structural imaging (MRI scans unless there 
was a contra-indication), the ACE-R, MMSE as part of their 
clinical care, and the TYM test. Many had additional neu-
ropsychological assessment.
Patients were diagnosed according to contemporary clini-
cal diagnostic criteria or by consensus at a multi-disciplinary 
team meeting into eight different diseases: behavioural vari-
ant frontotemporal dementia (bvFTD) [11], semantic dementia 
(SD) [12], DLB [13], PSP [14], CBS [15, 16], progressive 
non-fluent aphasia/non-fluent variant primary progressive 
aphasia (PNFA) [12] or by consensus at a multi-disciplinary 
team meeting as VaD or PCA.
The clinical team had access to all the SCT scores. 87% 
of patients were followed up (range 2–84 months, mean 
29.5 months), only the test scores at presentation was used in 
the analysis.
Healthy controls were age-matched and selected randomly 
from a previous study cohort [9]. Each group of non-Alzhei-
mer’s dementia patients was matched with a separate control 
group. Controls had no cognitive complaints or history of neu-
rological disease.
An AD cohort from an earlier study [9] with amnestic AD 
was used as an additional comparison group. They were of a 
similar age and had similar TYM scores to the non-Alzhei-
mer’s patients (average age Alzheimer patients 69 ± 8.5 years, 
non-Alzheimer dementia patients 67.5 ± 7.9 years; average 
TYM score for AD 33.2 ± 8.2, non-Alzheimer dementia 
patients 34.4 ± 8.9).
Administering the TYM test
The patient filled in the TYM test sheet under nurse supervi-
sion in a quiet room and the test was scored as described pre-
viously [9]. In contrast to the ACE-R and MMSE, the nurse 
supervises but does not administer the test. We used the cutoff 
of 42/50 for the TYM test as determined in earlier work on AD 
[9]. The TYM test and the scoring criteria can be downloaded 
free from https ://www.tymte st.com.
Statistical methods
Statistical analyses were performed in SPSSv25 and in 
Rv3.6.0. Group differences were assessed using independent 
Student’s t tests (equal variances not assumed) and corrected 
for multiple comparisons where appropriate using the Bonfer-
roni correction. Pearson’s correlations were used to examine 
the relationship between the TYM, ACE-R and MMSE scores.
Cronbach’s α was calculated to assess the reliability of the 
TYM test. Data from the patients and controls were used to 
plot the receiver-operating characteristic (ROC) curve. Sen-
sitivities, specificities, positive predictive value (PPV) and 
negative predictive value (NPV) were calculated using stand-
ard methods. The percentage of patients correctly classified in 
each diagnostic group were calculated.
In the text, the data are expressed as mean ± standard devia-
tion and the p values refer to independent Student’s t test.
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Results
Patient characteristics
One hundred and fifty-seven patients aged between 41 and 
83 years were recruited. Their average age was 67.5 years. 
The numbers and mean ages for each of the dementia groups 
are shown in Table 1. There were no adverse events.
Cronbach’s α was 0.75 (0.89 based on standardized 
items) suggesting the test was adequate to use for compar-
ing groups.
Combined analysis of non‑Alzheimer dementia 
patients
The average patient TYM score was 34.4 ± 9.0, compared 
with 46 ± 4.6 in the age-matched controls. The overall TYM 
scores and all the subtests (except copying) were signifi-
cantly lower than controls. The results are summarized in 
Table 2.
The TYM test (threshold 42) correctly identified 80% 
of the non-Alzheimer dementias versus controls. The area 
under the ROC curve was 0.89 with a PPV of 0.80 and NPV 
of 0.84 (Fig. 1). At the cutoff of 42, the sensitivity was 0.80 
and specificity was 0.84. The non-Alzheimer dementias are 
a varied group of diseases, but compared to controls they 
scored < 50% on the verbal fluency and sentence recall sub-
tests of the TYM.
In comparison to patients with Alzheimer’s disease, 
who had a similar overall score on the TYM, patients 
with non-Alzheimer dementias scored significantly better 
on orientation (p = 0.002), factual recall (p = 0.02), help 
given (p = 0.05) and recall (p < 0.001), had similar scores 
on naming, calculation and visuospatial skills but scored 
significantly lower on fluency (p = 0.01) and similarities 
(p = 0.004).
The ACE-R (threshold 82) detected 69% of patients with 
non-Alzheimer dementia, the MMSE (threshold 23) detected 
only 27%.
There were significant correlations between the TYM 
test and the ACE-R at the patient group level r = 0.83 
Table 1  Characteristics of the study patients
Diagnosis Num-
ber of 
patients
Mean age and range Sex M:F
Behavioural variant fron-
totemporal dementia
33 62.2 ± 8.2 21:12
Semantic dementia 24 66.9 ± 6.5 13:11
Progressive non-fluent 
aphasia
19 70.2 ± 7.7 9:10
Dementia with Lewy 
bodies
24 71.4 ± 4.8 14:10
Vascular dementia 11 71.0 ± 6.8 8:3
Progressive supranuclear 
palsy
22 70.4 ± 4.6 13:9
Corticobasal syndrome 17 67.7 ± 10.5 8:9
Posterior cortical atrophy 7 59.6 ± 7.4 1:6
Total 157 67.5 ± 8.0 87:70
Table 2  TYM overall scores and subtest scores in patients with unu-
sual dementias compared to controls
The p value refers to an independent t test, with unequal variance, 
correcting for multiple comparisons across the table
Patients
Mean ± SD
Controls
Mean ± SD
p value
Orientation 9.2 ± 1.4 9.9 ± 0.6 < 0.001
Copy 1.7 ± 0.7 1.8 ± 0.6 0.077
Factual recall 1.8 ± 1.1 2.6 ± 0.6 < 0.001
Sums 3.0 ± 1.1 3.7 ± 0.7 < 0.001
Fluency 1.5 ± 1.5 3.4 ± 1.1 < 0.001
Similarities 2.3 ± 1.6 3.3 ± 1.1 < 0.001
Naming 4.0 ± 1.4 4.9 ± 0.4 < 0.001
Visuospatial 1 1.7 ± 1.2 2.8 ± 0.7 < 0.001
Visuospatial 2 2.8 ± 1.4 3.7 ± 0.8 < 0.001
Recall 2.2 ± 2.5 5.0 ± 1.7 < 0.001
Help 4.2 ± 1.2 5.0 ± 0.2 < 0.001
TYM score 34.4 ± 9.0 46.0 ± 4.6 < 0.001
Fig. 1  ROC curve for the TYM test in the separation of patients with 
non-Alzheimer dementias from normal controls
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(p < 0.001) and between the TYM test and the MMSE 
r = 0.69 (p < 0.001).
Behavioural variant FTD
Patients with bvFTD performed significantly worse on the 
TYM test than controls: average 33.4 ± 10.6 vs 46.9 ± 2.4 
(p < 0.001). The TYM test detected 73% of cases. The area 
under the ROC curve was 0.93.
The average bvFTD patient score on the ACE-R was 68.5 
(detection rate 58%); the average score on the MMSE was 
23.6 (detection rate 48%).
All bvFTD patient subtest scores were significantly lower 
than controls (p < 0.008) except copying. Patients scored less 
than 50% of the control score on naming and sentence recall.
Perseveration of the drawing was rare but only seen in 
bvFTD patients (Fig. 2).
BvFTD patients scored less well on fluency and similari-
ties and better on sentence recall than AD patients. These 
were not significant.
Semantic dementia
22 patients with SD had predominantly left temporal lobe 
atrophy, and 2 had predominantly right-sided atrophy.
Patients performed significantly worse on the TYM test 
than controls: average 28.6 ± 8.2 vs 46.7 ± 3.3 (p < 0.001). 
The TYM test detected all cases of SD. The area under the 
ROC curve was 0.99.
The average patient score on the ACE-R was 56.6 (detec-
tion rate 96%); the average score on the MMSE was 23.5 
(detection rate 46%).
All subtest scores were significantly lower than controls 
(p < 0.03) except for copying and clock drawing. SD patients 
scored less than 50% of the control scores on factual recall, 
verbal fluency, similarities, naming and sentence recall.
SD patients scored less than 50% of the AD score on 
fluencies (p < 0.001), similarities (p < 0.001), naming 
(p < 0.001) and sentence recall (p = 0.02).
Progressive non‑fluent aphasia
Patients performed significantly worse on the TYM test than 
controls: average 32.8 ± 8.0 vs 46.4 ± 4.1 (p < 0.001). The 
TYM test detected 89% of cases. The area under the ROC 
curve was 0.94.
The average patient score on the ACE-R was 69.5 (detec-
tion rate 84%); the average score on the MMSE was 24.7 
(detection rate 58%).
All PNFA patient subtest scores were significantly lower 
than controls except orientation and copying. Patients scored 
less than 75% of the controls scores on factual recall, simi-
larities, visuospatial 1 and 2, sentence recall and help.
PNFA patients scored less well on fluency and similari-
ties but better on sentence recall than AD patients. These 
changes were not significant.
Dementia with Lewy bodies
Patients with DLB performed significantly worse on the 
TYM test than controls: average 32.6 ± 7.6 vs 46.2 ± 6.1 
(p < 0.001). The TYM test detected 88% of cases. The area 
under the ROC curve was 0.93.
The average patient score on the ACE-R was 72.8 (detec-
tion rate 88%); the average score on the MMSE was 24.9 
(detection rate 21%).
All DLB patient subtest scores were significantly lower 
than controls (p < 0.02) except for copying and similarities, 
they scored less than 50% of the controls scores on fluency, 
visuospatial 1 and sentence recall. Typically, the clock draw-
ing was small and disorganized (Fig. 3).
DLB patients scored less well on fluency (p = 0.03) and 
better on factual and sentence recall (not significant) than 
AD patients.
Vascular dementia
Patients with VaD performed significantly worse on the 
TYM test than controls: average 36.7 ± 8.2 vs 43.6 ± 4.8 
(p < 0.026). The TYM test detected 73% of cases. The area 
under the ROC curve was 0.76.
The average patient score on the ACE-R was 76.3 (detec-
tion rate 73%); the average score on the MMSE was 25.7 
(detection rate 27%).
VaD patient scores for naming and visuospatial 1 were 
significantly lower that controls (p < 0.05).
VaD patients scored better on sentence recall (not signifi-
cant) than AD patients.
Fig. 2  TYM test sheet filled in by a patient with bvFTD showing per-
severation in drawing a clock
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Progressive supranuclear palsy
Patients with PSP performed significantly worse on the 
TYM test than controls: average 38.6 ± 6.5 vs 44.6 ± 5.9 
(p = 0.002). The TYM test detected 77% of cases. The area 
under the ROC curve was 0.79.
The average patient score on the ACE-R was 79.7 (detec-
tion rate 59%); the average score on the MMSE was 26.5 
(detection rate 18%).
PSP patients scored significantly worse than controls on 
sums, fluencies and visuospatial tasks (p < 0.009).
PSP patients scored better on orientation (p < 0.001), 
factual (p = 0.004) and sentence recall (p < 0.001) and help 
given (p = 0.01) than AD patients.
Corticobasal syndrome
Patients with CBS performed significantly worse on the 
TYM test than controls: average 41.5 ± 4.5 vs 46.2 ± 6.8 
(p < 0.024). The TYM test detected 53% of cases of CBS. 
The area under the ROC curve was 0.76.
The average CBS patient score on the ACE-R was 85 
(detection rate 24%); the average score on the MMSE was 
27.5 (detection rate 12%).
CBS patients scored significantly lower than controls on 
copying, fluency and visuospatial tasks (p < 0.05).
CBS patients scored better than AD patients on orien-
tation (p < 0.001), factual (p < 0.001) and sentence recall 
(p < 0.09).
CBS patients scored better on sentence recall than 
patients with other non-Alzheimer dementias.
Posterior cortical atrophy
PCA patients performed significantly worse on the TYM 
test than controls average 35.4 ± 5.0vs 46.3 ± 6.4 (p = 0.005). 
The TYM test detected 86% of cases of PCA. The area under 
the ROC curve was 0.88.
The average patient score on the ACE-R was 78.7 (detec-
tion rate 57%); the average score on the MMSE was 26.1 
(none detected).
PCA patients scored significantly worse than controls 
(p < 0.04) on sums, visuospatial tasks and help given. 
Visuospatial tasks were particularly poorly done and some 
patients showed an inability to see the whole figure (Fig. 4).
Compared to typical Alzheimer patients, PCA patients 
scored better on orientation (p = 0.002) fluency and factual/
sentence recall (not significant). They scored less well on 
sums and visuospatial tasks (not significant).
Compared to the non-Alzheimer dementias, PCA patients 
scored well on fluencies but worse on sums and the visuos-
patial tasks.
Table 3 summarizes the TYM scores and subset scores 
for the different diseases.
Discussion
The purpose of this study was to establish whether the 
TYM test can detect and support a clinical diagnosis of 
a non-Alzheimer dementia. The TYM test should not be 
used in isolation to diagnose dementia [17]. We compared 
the TYM test to 2 more established tests—the ACE-R and 
MMSE. Strengths of this study include the large number of 
patients with unusual dementias and the comparison with 
two groups: healthy controls and patients with typical AD.
The study has a number of limitations:
The diagnoses rested on clinical evaluation and consensus 
diagnostic criteria, not neuropathology. However, the TYM 
is intended for use in clinical settings. We recognize that 
some patients with CBS have Alzheimer disease pathology 
[16], and the majority of patients with PCA have Alzhei-
mer’s neuropathology.
Some diagnoses changed during the study—for example 
a patient with PNFA later developed PSP. In these cases, the 
original clinical diagnosis was used. Some non-Alzheimer 
dementias are rare and we did not recruit equal numbers of 
patients in every group.
Recruitment was prospective but prolonged. A high 
percentage of patients were followed up for an average 
of 29 months. There may be ascertainment bias result-
ing from assessment in a specialized clinic, this is likely 
in VaD where patients with less typical presentations are 
likely to be referred to a memory clinic. The sample of 
VaD in this study is small and likely to be atypical.
Fig. 3  TYM test sheet filled in by a patient with DLB showing a 
small, poorly organized clock face
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The standardized thresholds for the SCTs were based 
on their performance in the diagnosis of typical AD, and 
alternative thresholds may improve performance for non-
Alzheimer’s dementias.
This study was a proof-of-concept study. We have 
established that the TYM test detects a large majority of 
non-Alzheimer dementias. The TYM and ACE-R are both 
useful in detecting unusual dementias. The detection rate 
is dependent upon the chosen threshold and this study does 
not establish one as superior to the other. The ease and 
speed of testing is an advantage for TYM in many settings. 
The study showed that the TYM test and the ACE-R are 
superior to the MMSE in the detection of non-Alzheimer 
dementias.
There have been limited studies of the TYM test in non-
Alzheimer dementias. A small number of patients with non-
Alzheimer dementias were included in the original valida-
tion study [9]. A study recruited 47 individuals with DLB 
and 97 with AD in a clinic in Tokyo [18]. This study found 
that patients with DLB scored better than patients with AD 
on the memory parts of the TYM but did worse on similari-
ties, sums and naming. These results agree with the current 
study, although in our study patients with DLB also did 
worse on fluency and the first visuospatial task.
The MMSE may be insensitive to non-Alzheimer demen-
tias [6]. The MMSE detected just 27% of FTD cases in the 
original ACE validation study [6], a small study found it 
detected just 24% of cases of bvFTD [19]. The lack of sen-
sitivity to non-Alzheimer’s dementias is strongly supported 
in this study with an overall detection rate of just 27% com-
pared to 80% for the TYM test.
The results of the current study are in agreement with 
previous studies of the usefulness of the ACE in detecting 
FTD. In the current study, using the threshold of 83, the 
ACE-R detected 73% of all cases of FTD but had a lower 
detection rate for behavioural variant FTD (58%). If the three 
groups of FTD patients in this study (bvFTD, SD and PNFA) 
are combined then the current results are very similar to the 
original study ACE validation study (76.5% vs 73%) [6]. A 
small study [19] found that the ACE detected 83% of cases 
of FTD, but found that the ACE was less useful in bvFTD. 
A study using the ACE in semantic dementia found a very 
similar pattern and overall score (56.7) to the current study 
[20].
The ACE tests have also found to be useful in patients 
with PNFA [21, 22] and in the detection of cognitive deficits 
in patients with parkinsonian syndromes [22–24].
Fourteen patients with VaD were included in the original 
ACE study [6] and the ACE detected 57% of cases with a 
cutoff of 83 and the MMSE detected 43%. This compares to 
73% and 27% in the current study.
Fig. 4  TYM test sheet filled in by a patient with PCA showing the 
patient not seeing the whole picture in spotting the letter in the first 
visuospatial task
Table 3  TYM scores and subtest scores for each form of unusual dementia, all non-Alzheimer dementias (including CBS and PCA), controls 
and patients with typical amnestic Alzheimer’s disease (AD)
bvFTD SD DLB VaD PSP CBS PNFA PCA All non-AD Controls Typical AD
Orientation 8.7 9.3 8.8 9.5 9.5 9.8 9.3 9.6 9.2 9.9 8.3
Copy 1.7 1.9 1.7 1.8 1.6 1.4 1.5 1.7 1.7 1.8 1.7
Factual recall 1.8 1.1 1.9 1.8 2.1 2.5 1.4 2.0 1.8 2.6 1.4
Sums 3.1 3.3 2.7 2.8 3.0 3.2 3.0 1.7 3.0 3.7 3.1
Fluency 1.6 0.6 1.2 2 1.7 2.4 1.2 3.1 1.5 3.4 2.2
Similarities 2.0 1.0 2.5 2.9 2.8 3.4 2.1 3.1 2.3 3.3 3.0
Naming 4.0 2.2 4.3 4.1 4.5 4.8 4.6 4.4 4.0 4.9 4.4
Visuospatial 1 1.8 1.8 1.4 1.9 1.8 1.9 1.8 1.0 1.7 2.8 1.8
Visuospatial 2 3.3 3.0 2.3 2.8 2.5 3.3 2.6 1.7 2.8 3.7 2.9
Sentence Recall 1.7 0.2 1.7 2.3 4.3 4.6 1.5 3.0 2.2 5.0 0.9
Help 3.7 4.2 4.3 4.8 4.6 4.6 3.9 4.0 4.2 5.0 3.7
TYM score (0–50) 33.4 28.6 32.6 36.7 38.5 41.5 32.8 35.4 34.4 46.0 33.2
ACE-R (0–100) 68.5 56.6 72.8 76.3 79.7 85.0 69.5 78.7 72.1 66.9
MMSE (0–30) 23.6 23.5 24.9 25.7 26.5 27.5 24.7 26.1 25.1 22.5
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Studies have examined the use of the MoCA in forms of 
VaD [25, 26] and it has been shown to identify cognitive 
deficits in patients post-stroke/TIA who passed the MMSE 
[25]. The MoCA detects cognitive deficits in patients with 
Parkinson’s disease dementia [26] and can detect cogni-
tive deficits in patients with Parkinson’s disease who pass 
the MMSE. The MoCA had high sensitivity for detecting 
bvFTD from normal controls and performed better than the 
MMSE [27].
There is often an emphasis on the total score in inter-
preting short cognitive tests [17]. The total TYM score is 
of value if used in this way. Administering the TYM test 
personally and examining the pattern of scoring afterwards 
offers greater insights.
The TYM test detected 80% of patients with non-Alzhei-
mer dementias. There were two main reasons for the TYM 
test failing to detect patients with degenerative disease. The 
first was that the patients had very mild cognitive problems. 
The lowest detection rate for the TYM test was in CBS. 
Many patients initially presenting with CBS have very mild 
cognitive problems, the 8 patients with CBS who passed the 
TYM test fall into this category (their average score on the 
ACE-R was 93/100—close to the control average of 94 [7]). 
This also applies to some patients with PSP, PNFA and VaD.
The second reason for passing the TYM test was that 
patients had focal cognitive deficits. This is illustrated by a 
PCA patient who just passed the TYM test scoring 43/50. 
However, on visuospatial tasks she scored only 4/7 (control 
average 6.5/7). Some patients with bvFTD just passed the 
TYM test but did relatively poorly on fluencies or similari-
ties. These cases illustrate the importance of looking at the 
TYM sheet and the pattern of scoring not just the overall 
score to support a diagnosis.
In the following paragraphs, we summarize the patterns 
and interpretation that are useful in the different forms of 
dementia.
Behavioural variant FTD
The pattern of the TYM scoring in bvFTD is distinct from 
Alzheimer’s disease and controls but was similar to other 
non-Alzheimer dementias. Patients with bvFTD scored bet-
ter on memory than patients with AD but worse on fluency 
and similarities. The diagnosis of bvFTD can be suspected 
on inspection of the TYM sheet as the patient may persever-
ate in drawing (Fig. 2) or add comments to the sheet.
Semantic dementia
Semantic dementia has a distinct pattern on the TYM test. 
The pattern of good orientation and clock drawing coupled 
with very poor similarities, naming, fluencies and sentence 
recall (due to language rather than memory problems) 
distinguished semantic dementia from controls, AD and 
other dementias.
Progressive non fluent aphasia
Patients with PNFA scored well on memory tests compared 
to patients with AD. They did better on sentence recall than 
other dementias with the exception of patients with PSP or 
CBS, reflecting the clinicopathological overlap between 
these three disorders. They scored especially poorly on the 
fluency test.
Dementia with Lewy bodies
Patients with DLB score poorly on the TYM test compared 
to controls. As a group, they scored poorer on fluency and 
visuospatial tasks compared to AD patients whilst scoring 
better on memory. These differences are not sufficient to 
allow distinction of these dementias on the TYM test alone. 
Compared to other non-Alzheimer dementias, patients with 
DLB score worse on the visuospatial tasks and sentence 
recall. A small disorganized clock (Fig. 2) is typical of DLB 
but not diagnostic.
Vascular dementia
There was no pattern on the TYM test to distinguish VaD 
from other forms of dementia.
Progressive supranuclear palsy and corticobasal 
syndrome
Patients with PSP and CBS often develop cognitive prob-
lems, but it is variable and may not reach the threshold for 
a dementia [28, 29]. As a group they scored better on the 
TYM test compared to the other groups. Patients scored 
strikingly better on sentence recall and factual recall than 
in other dementias, but poorly on fluencies and similarities. 
Some CBS patients found copying the sentence difficult.
Posterior cortical atrophy
Patients with PCA had a distinct pattern on the TYM test 
which distinguished them from controls and other patients 
with poor scores on calculation and the visuospatial tasks 
with good orientation, fluency and sentence recall. Patients 
with severe problems found copying the sentence difficult.
In summary, the TYM test detects the majority of non-
Alzheimer dementias and is superior to the MMSE in this 
task. The TYM requires minimal time and supervision, 
making it highly suited to primary and secondary health-
care settings.
 Journal of Neurology
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